Detalhe da pesquisa
1.
Prognostic impact of DDX41 germline mutations in intensively treated acute myeloid leukemia patients: an ALFA-FILO study.
Blood;
140(7): 756-768, 2022 08 18.
Artigo
em Inglês
| MEDLINE
| ID: mdl-35443031
2.
Genetic identification of patients with AML older than 60 years achieving long-term survival with intensive chemotherapy.
Blood;
138(7): 507-519, 2021 08 19.
Artigo
em Inglês
| MEDLINE
| ID: mdl-34410352
3.
Prognostic significance of concurrent gene mutations in intensively treated patients with IDH-mutated AML: an ALFA study.
Blood;
137(20): 2827-2837, 2021 05 20.
Artigo
em Inglês
| MEDLINE
| ID: mdl-33881523
4.
A personalized approach to guide allogeneic stem cell transplantation in younger adults with acute myeloid leukemia.
Blood;
137(4): 524-532, 2021 01 28.
Artigo
em Inglês
| MEDLINE
| ID: mdl-32871585
5.
Gemtuzumab ozogamicin for de novo acute myeloid leukemia: final efficacy and safety updates from the open-label, phase III ALFA-0701 trial.
Haematologica;
104(1): 113-119, 2019 01.
Artigo
em Inglês
| MEDLINE
| ID: mdl-30076173
6.
An update of current treatments for adult acute myeloid leukemia.
Blood;
127(1): 53-61, 2016 Jan 07.
Artigo
em Inglês
| MEDLINE
| ID: mdl-26660429
7.
Arsenic trioxide is required in the treatment of newly diagnosed acute promyelocytic leukemia. Analysis of a randomized trial (APL 2006) by the French Belgian Swiss APL group.
Haematologica;
103(12): 2033-2039, 2018 12.
Artigo
em Inglês
| MEDLINE
| ID: mdl-30026341
8.
Lenalidomide combined with intensive chemotherapy in acute myeloid leukemia and higher-risk myelodysplastic syndrome with 5q deletion. Results of a phase II study by the Groupe Francophone Des Myélodysplasies.
Haematologica;
102(4): 728-735, 2017 04.
Artigo
em Inglês
| MEDLINE
| ID: mdl-28034993
9.
Systemic inflammatory and autoimmune manifestations associated with myelodysplastic syndromes and chronic myelomonocytic leukaemia: a French multicentre retrospective study.
Rheumatology (Oxford);
55(2): 291-300, 2016 Feb.
Artigo
em Inglês
| MEDLINE
| ID: mdl-26350487
10.
A randomized phase II trial of azacitidine +/- epoetin-ß in lower-risk myelodysplastic syndromes resistant to erythropoietic stimulating agents.
Haematologica;
101(8): 918-25, 2016 08.
Artigo
em Inglês
| MEDLINE
| ID: mdl-27229713
11.
Incidence of ATRX mutations in myelodysplastic syndromes, the value of microcytosis.
Am J Hematol;
90(8): 737-8, 2015 Aug.
Artigo
em Inglês
| MEDLINE
| ID: mdl-26017030
12.
Azacitidine in untreated acute myeloid leukemia: a report on 149 patients.
Am J Hematol;
89(4): 410-6, 2014 Apr.
Artigo
em Inglês
| MEDLINE
| ID: mdl-24375487
13.
Comparison of high-dose cytarabine and timed-sequential chemotherapy as consolidation for younger adults with AML in first remission: the ALFA-9802 study.
Blood;
118(7): 1754-62, 2011 Aug 18.
Artigo
em Inglês
| MEDLINE
| ID: mdl-21690555
14.
Molecular predictors of response to decitabine in advanced chronic myelomonocytic leukemia: a phase 2 trial.
Blood;
118(14): 3824-31, 2011 Oct 06.
Artigo
em Inglês
| MEDLINE
| ID: mdl-21828134
15.
Prognostic factors for response and overall survival in 282 patients with higher-risk myelodysplastic syndromes treated with azacitidine.
Blood;
117(2): 403-11, 2011 Jan 13.
Artigo
em Inglês
| MEDLINE
| ID: mdl-20940414
16.
The prognosis of CALM-AF10-positive adult T-cell acute lymphoblastic leukemias depends on the stage of maturation arrest.
Haematologica;
98(11): 1711-7, 2013 Nov.
Artigo
em Inglês
| MEDLINE
| ID: mdl-23831922
17.
Outcome of older patients with acute myeloid leukemia in first relapse.
Am J Hematol;
88(9): 758-64, 2013 Sep.
Artigo
em Inglês
| MEDLINE
| ID: mdl-23749683
18.
UBTF tandem duplications define a distinct subtype of adult de novo acute myeloid leukemia.
Leukemia;
37(6): 1245-1253, 2023 06.
Artigo
em Inglês
| MEDLINE
| ID: mdl-37085611
19.
Very long-term outcome of acute promyelocytic leukemia after treatment with all-trans retinoic acid and chemotherapy: the European APL Group experience.
Blood;
115(9): 1690-6, 2010 Mar 04.
Artigo
em Inglês
| MEDLINE
| ID: mdl-20018913
20.
Fractionated doses of gemtuzumab ozogamicin with escalated doses of daunorubicin and cytarabine as first acute myeloid leukemia salvage in patients aged 50-70-year old: a phase 1/2 study of the acute leukemia French association.
Am J Hematol;
87(1): 62-5, 2012 Jan.
Artigo
em Inglês
| MEDLINE
| ID: mdl-22072535